Sung Ji Nam
Stock Analyst at Scotiabank
(2.57)
# 1,656
Out of 5,182 analysts
81
Total ratings
47.76%
Success rate
2.33%
Average return
Main Sectors:
Stocks Rated by Sung Ji Nam
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GH Guardant Health | Maintains: Sector Outperform | $57 → $60 | $84.86 | -29.30% | 6 | Jul 31, 2025 | |
| TECH Bio-Techne | Maintains: Sector Outperform | $90 → $75 | $58.49 | +28.23% | 3 | Jul 11, 2025 | |
| DHR Danaher | Upgrades: Sector Outperform | $275 | $198.14 | +38.79% | 2 | Jul 11, 2025 | |
| TMO Thermo Fisher Scientific | Upgrades: Sector Outperform | $590 | $531.67 | +10.97% | 15 | Jul 11, 2025 | |
| ILMN Illumina | Downgrades: Sector Perform | $125 | $132.26 | -5.49% | 10 | Jul 11, 2025 | |
| CSTL Castle Biosciences | Maintains: Sector Outperform | $44 → $40 | $24.62 | +62.47% | 6 | May 21, 2025 | |
| BDSX Biodesix | Maintains: Sector Outperform | $60 → $40 | $12.66 | +215.96% | 2 | May 21, 2025 | |
| MYGN Myriad Genetics | Downgrades: Sector Perform | $20 → $6 | $5.19 | +15.61% | 4 | May 21, 2025 | |
| BNGO Bionano Genomics | Maintains: Sector Perform | $1 → $4 | $1.28 | +212.50% | 6 | Apr 2, 2025 | |
| PACB Pacific Biosciences of California | Maintains: Sector Outperform | $6 → $2 | $1.60 | +25.00% | 5 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $10 → $12 | $14.54 | -17.44% | 2 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Sector Outperform | $430 → $450 | $326.20 | +37.95% | 2 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $54 → $62 | $57.62 | +7.60% | 5 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $40 → $44 | $34.04 | +29.26% | 4 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $35 | $17.57 | +99.20% | 4 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $6 | $2.74 | +118.98% | 2 | Jun 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $16.17 | - | 3 | Nov 24, 2020 |
Guardant Health
Jul 31, 2025
Maintains: Sector Outperform
Price Target: $57 → $60
Current: $84.86
Upside: -29.30%
Bio-Techne
Jul 11, 2025
Maintains: Sector Outperform
Price Target: $90 → $75
Current: $58.49
Upside: +28.23%
Danaher
Jul 11, 2025
Upgrades: Sector Outperform
Price Target: $275
Current: $198.14
Upside: +38.79%
Thermo Fisher Scientific
Jul 11, 2025
Upgrades: Sector Outperform
Price Target: $590
Current: $531.67
Upside: +10.97%
Illumina
Jul 11, 2025
Downgrades: Sector Perform
Price Target: $125
Current: $132.26
Upside: -5.49%
Castle Biosciences
May 21, 2025
Maintains: Sector Outperform
Price Target: $44 → $40
Current: $24.62
Upside: +62.47%
Biodesix
May 21, 2025
Maintains: Sector Outperform
Price Target: $60 → $40
Current: $12.66
Upside: +215.96%
Myriad Genetics
May 21, 2025
Downgrades: Sector Perform
Price Target: $20 → $6
Current: $5.19
Upside: +15.61%
Bionano Genomics
Apr 2, 2025
Maintains: Sector Perform
Price Target: $1 → $4
Current: $1.28
Upside: +212.50%
Pacific Biosciences of California
Mar 25, 2025
Maintains: Sector Outperform
Price Target: $6 → $2
Current: $1.60
Upside: +25.00%
Feb 13, 2025
Maintains: Sector Outperform
Price Target: $10 → $12
Current: $14.54
Upside: -17.44%
Feb 13, 2025
Upgrades: Sector Outperform
Price Target: $430 → $450
Current: $326.20
Upside: +37.95%
Feb 4, 2025
Maintains: Sector Outperform
Price Target: $54 → $62
Current: $57.62
Upside: +7.60%
Nov 8, 2024
Maintains: Sector Outperform
Price Target: $40 → $44
Current: $34.04
Upside: +29.26%
Nov 5, 2024
Maintains: Buy
Price Target: $40 → $35
Current: $17.57
Upside: +99.20%
Jun 29, 2023
Assumes: Buy
Price Target: $6
Current: $2.74
Upside: +118.98%
Nov 24, 2020
Downgrades: Neutral
Price Target: n/a
Current: $16.17
Upside: -